Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02

被引：0

作者：

Janne, P. ^{[1
]}

Goto, Y. ^{[2
]}

Kubo, T. ^{[3
]}

Ninomiya, K. ^{[4
]}

Kim, S. -W. ^{[5
]}

Planchard, D. ^{[6
]}

Ahn, M. -J. ^{[7
]}

Smit, E. F. ^{[8
]}

de Langen, A. J. ^{[9
]}

Perol, M. ^{[10
]}

Pons-Tostivint, E. ^{[11
]}

Novello, S. ^{[12
]}

Hayashi, H. ^{[13
]}

Shimizu, J. ^{[14
]}

Kim, D. -W. ^{[15
]}

Pereira, K. ^{[16
]}

Cheng, F. -C. ^{[16
]}

Taguchi, A. ^{[16
]}

Cheng, Y. ^{[16
]}

Goto, K. ^{[17
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Natl Canc Ctr, Tokyo, Japan

[3] Okayama Univ Hosp, Ctr Clin Oncol, Okayama, Japan

[4] Okayama Univ Hosp, Okayama, Japan

[5] Asan Med Ctr, Seoul, South Korea

[6] Gustave Roussy, Villejuif, France

[7] Samsung Med Ctr, Seoul, South Korea

[8] Leiden Univ, Med Ctr, Leiden, Netherlands

[9] Netherlands Canc Inst, Amsterdam, Netherlands

[10] Leon Berard Ctr, Lyon, France

[11] Univ Nantes, Ctr Hosp Univ Nantes, Nantes, France

[12] Univ Turin, Dept Oncol, Azienda Osped Univ San Luigi Gonzaga, Orbassano, Italy

[13] Kindai Univ Hosp, Osaka, Japan

[14] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[15] Seoul Natl Univ Hosp, Seoul, South Korea

[16] Daiichi Sankyo Inc, Basking Ridge, NJ USA

[17] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期

关键词：

NSCLC; trastuzumab deruxtecan; HER2;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA13.10

引用

页码：S148 / S148

页数：1

共 50 条

[1] Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial
Goto, Koichi
Goto, Yasushi
Kubo, Toshio
Ninomiya, Kiichiro
Kim, Sang-We
Planchard, David
Ahn, Myung-Ju
Smit, Egbert F.
de Langen, Adrianus Johannes
Perol, Maurice
Pons-Tostivint, Elvire
Novello, Silvia
Hayashi, Hidetoshi
Shimizu, Junichi
Kim, Dong-Wan
Kuo, Chih-Hsi
Yang, James Chih-Hsin
Pereira, Kaline
Cheng, Fu-Chih
Taguchi, Ayumi
Cheng, Yingkai
Feng, Wenqin
Tsuchihashi, Zenta
Janne, Pasi A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (31) : 4852 - +
[2] Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial
Goto, K.
Sang-We, K.
Kubo, T.
Goto, Y.
Ahn, M-J.
Planchard, D.
Kim, D-W.
Yang, J. C-H.
Yang, T-Y.
Pereira, K. M. C.
Saxena, K.
Shiga, R.
Cheng, Y.
Aregay, M.
Janne, P. A.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1422 - S1422
[3] Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non-small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02.
Janne, Pasi A.
Goto, Yasushi
Kubo, Toshio
Ninomiya, Kiichiro
Kim, Sang-We
Planchard, David
Ahn, Myung-Ju
Smit, Egbert F.
De langen, Adrianus Johannes
Perol, Maurice
Pons-Tostivint, Elvire
Novello, Silvia
Hayashi, Hidetoshi
Shimizu, Junichi
Kim, Dong-Wan
Pereira, Kaline
Cheng, Fu-Chih
Taguchi, Ayumi
Cheng, Yingkai
Goto, Koichi
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[4] Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial (vol 41, pg 4852, 2023)
Goto, Koichi
Goto, Yasushi
Kubo, Toshio
Ninomiya, Kiichiro
Kim, Sang-We
Planchard, David
Ahn, Myung-Ju
Smit, Egbert F.
de Langen, Adrianus Johannes
Perol, Maurice
Pons-Tostivint, Elvire
Novello, Silvia
Hayashi, Hidetoshi
Shimizu, Junichi
Kim, Dong-Wan
Kuo, Chih-Hsi
Yang, James Chih-Hsin
Pereira, Kaline
Cheng, Fu-Chih
Taguchi, Ayumi
Cheng, Yingkai
Feng, Wenqin
Tsuchihashi, Zenta
Janne, Pasi A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (04) : 485 - 485
[5] Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer
Li, Bob T.
Smit, Egbert F.
Goto, Yasushi
Nakagawa, Kazuhiko
Udagawa, Hibiki
Mazieres, Julien
Nagasaka, Misako
Bazhenova, Lyudmila
Saltos, Andreas N.
Felip, Enriqueta
Pacheco, Jose M.
Perol, Maurice
Paz-Ares, Luis
Saxena, Kapil
Shiga, Ryota
Cheng, Yingkai
Acharyya, Suddhasatta
Vitazka, Patrik
Shahidi, Javad
Planchard, David
Janne, Pasi A.
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (03): : 241 - 251
[6] Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial (vol 42, 10.1200/JCO-24-01883, 2024)
Goto, Koichi
Goto, Yasushi
Kubo, Toshio
Ninomiya, Kiichiro
Kim, Sang-We
Planchard, David
Ahn, Myung-Ju
Smit, Egbert F.
de Langen, Adrianus Johannes
Perol, Maurice
Pons-Tostivint, Elvire
Novello, Silvia
Hayashi, Hidetoshi
Shimizu, Junichi
Kim, Dong-Wan
Kuo, Chih-Hsi
Yang, James Chih-Hsin
Pereira, Kaline
Cheng, Fu-Chih
Taguchi, Ayumi
Cheng, Yingkai
Feng, Wenqin
Tsuchihashi, Zenta
Janne, Pasi A.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (30) : 3635 - 3635
[7] Trastuzumab deruxtecan shows durable activity in HER2-mutant non-small cell lung cancer
O'Rourke, Kate
CANCER, 2022, 128 (05) : 938 - 938
[8] DESTINY-Lung01 Trial Investigators Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer
Sharayah, Ahmad
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209 (06) : 749 - 750
[9] Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond
Vathiotis, Ioannis A.
Bafaloukos, Dimitrios
Syrigos, Konstantinos N. N.
Samonis, George
CANCERS, 2023, 15 (04)
[10] Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01
Nakagawa, K.
Nagasaka, M.
Felip, E.
Pacheco, J.
Baik, C.
Goto, Y.
Saltos, A.
Li, B.
Udagawa, H.
Gadgeel, S.
Murakami, H.
Planchard, D.
Bazhenova, L.
Paz-Ares, L.
Perol, M.
Mazieres, J.
Barlesi, F.
Saxena, K.
Shiga, R.
Acharyya, S.
Cheng, Y.
Shahidi, J.
Janne, P.
Smit, E.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S109 - S110

← 1 2 3 4 5 →